Using Monoclonal Antibodies for Prevention of COVID-19

Can Pemivibart (Pemgarda) Offer Better COVID-19 Protection Than Vaccines for High-Risk Groups?Подробнее

Monoclonal Antibodies and Vaccine BoostsПодробнее

Vaccines vs Monoclonal Antibodies for COVID-19: Complementary Approaches to Tackling the PandemicПодробнее

Optimizing Access to Monoclonal Antibodies for COVID-19: US PerspectiveПодробнее

Neutralizing the Virus: A Focus on SARS-CoV-2–Specific Monoclonal AntibodiesПодробнее

Monoclonal Antibodies and Booster ShotsПодробнее

New Treatment Options for High-Risk COVID-19 Patients With Mild to Moderate DiseaseПодробнее

Advanced Antibody Discovery Platform Generates COVID-19 Antibody Therapy with Ian Chan AbproПодробнее

Challenges and Opportunities in the Use of Monoclonal Antibody Therapy for COVID-19Подробнее

Postexposure Prophylaxis for COVID-19 Prevention: Where Do We Stand?Подробнее

Toward a Brighter Future for Preventing COVID-19 in Patients With Hematologic MalignanciesПодробнее

13th Annual DTRMPS: Pharmacometric modeling of COVID-19 monoclonal antibodies: a dose selection...Подробнее

Covid, Flu & RSV; Measles Status Update: New COVID Prevention / Monoclonal (Pemgarda)Подробнее

Next-Generation Monoclonal Antibodies for COVID-19: A Clinical UpdateПодробнее

Monoclonal Antibodies: Looking Beyond COVID-19Подробнее

Optimizing Access to Monoclonal Antibodies for COVID-19 Infection: The Global PerspectiveПодробнее

The Potential of Monoclonal Antibodies: Fighting COVID 19 and BeyondПодробнее

TWIV 1088: Clinical update with Dr. Daniel GriffinПодробнее

Development of Next-Generation Prophylactic Antibodies for COVID-19Подробнее

Understanding the Potential of Antibodies for COVID-19Подробнее